Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 6/20 | 0.46 |
| ▸ | CA1 | P00915 | 6/20 | 0.46 |
| ▸ | CA2 | P00918 | 6/20 | 0.46 |
| ▸ | CA7 | P43166 | 6/20 | 0.46 |
| ▸ | CA9 | Q16790 | 6/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.46 |
| ▸ | GABRP | O00591 | 6/20 | 0.46 |
| ▸ | GABRD | O14764 | 6/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.46 |
| ▸ | GABRE | P78334 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10228362 | 0.84 | CYP1A2 (0.50) | CYP1A2CA12CA1CA2CA7 | |
| SCHEMBL3712576 | 0.83 | ESR1 (0.50) | CYP1A2NR1H2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL13472450 | 0.81 | ALDH1A1 (0.47) | CYP1A2CA12CA1CA2CA7 | |
| SCHEMBL549184 | 0.81 | CYP1A2 (0.47) | CYP1A2CA12CA1CA2CA7 | |
| SCHEMBL17979291 | 0.79 | LCK (0.45) | CYP1A2CA12CA1CA2CA7 | |
| SCHEMBL11528320 | 0.78 | CYP1A2 (0.45) | CYP1A2CA12CA1CA2CA7 | |
| SCHEMBL25276749 | 0.77 | CYP1A2 (0.44) | CYP1A2CA2GABRA1GABRG2GABRB3 | |
| SCHEMBL29537507 | 0.77 | CYP1A2 (0.44) | CYP1A2CA2GABRA1GABRG2GABRB3 | |
| SCHEMBL21441912 | 0.76 | LCK (0.35) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL5262334 | 0.75 | GABRA1 (0.52) | CYP1A2CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448391-B2 | Bicyclic derivatives for treating endoparasites | ELANCO TIERGESUNDHEIT AG (CH) | 2025-10-21 | — | — | US | disclosed |
| CN-114206860-B | Bicyclic derivatives for the treatment of endoparasites | 礼蓝动物保健有限公司 | 2025-02-18 | — | — | CN | disclosed |
| EP-3897842-B1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2025-01-29 | — | — | EP | disclosed |
| US-20240360116-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (SZ) | 2024-10-31 | — | — | US | disclosed |
| CN-113490527-B | Bicyclic derivatives | 瑞士伊兰科动物保健有限公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-116888124-A | Bicyclic derivatives | 礼蓝动物保健有限公司 | 2023-10-13 | — | — | CN | disclosed |
| EP-4255911-A1 | BICYCLIC DERIVATIVES | Elanco Tiergesundheit AG (CH) | 2023-10-11 | — | — | EP | disclosed |
| US-20220242857-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | ELANCO TIERGESUNDHEIT AG (CH) | 2022-08-04 | — | — | US | disclosed |
| WO-2022117783-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2022-06-09 | — | — | WO | disclosed |
| CN-114588157-A | Methods and compositions for treating HIV-related disorders | CHDI基金会股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090030009-A1 | Heterobicyclic Carboxamides as Inhibitors for Kinases | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2009006389-A2 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| EP-1996578-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| CN-101258147-A | 4-piperazin-1-yl-4-benzo [ B ] thiophene derivatives for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| EP-1919907-A2 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008009487-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030009-A1 | Heterobicyclic Carboxamides as Inhibitors for Kinases | PHKG1, MAP3K20, CDK2 | CYP1A2 2732/4885CA12 3478/4885CA1 2954/4885 |
| US-12448391-B2 | Bicyclic derivatives for treating endoparasites | TBXA2R, PIGS, CYCS | CYP1A2 92/4885CA12 2785/4885CA1 1986/4885 |
| US-20240360116-A1 | BICYCLIC DERIVATIVES | FABP3, CYCS, TNNI3 | CYP1A2 33/4885CA12 1838/4885CA1 1513/4885 |
| US-20090036419-A1 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | CYP1A2 4510/4885CA12 4293/4885CA1 4280/4885 |
| US-20220242857-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | TBXA2R, PIGS, CYCS | CYP1A2 92/4885CA12 2785/4885CA1 1986/4885 |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | GRIN2C, GRIN2B, PMP22 | CYP1A2 103/4885CA12 3345/4885CA1 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.